Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company combining immunology therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), announced a strategic refocusing of its R&D portfolio following the Aug. 31 expiration and termination of its option and license arrangements with PinCell S.r.l. relating to PC111. Scinai said the decision was not driven by any new negative scientific finding regarding PC111 and will allow the company to concentrate R&D resources on its NanoAb platform while preserving capital and management capacity for its CDMO business. Scinai is advancing two IL-17 programs within the NanoAb platform, including an intradermal psoriasis program for which approximately €12 million in grant financing is under evaluation in Poland. The company also reported approximately $3.1 million in committed CDMO customer orders as of Aug. 16 and continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition and additional business opportunities.
To view the full press release, visit https://ibn.fm/nnx0Z
About Scinai Immunotherapeutics.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.
Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
